Thomas Neff, Chairman of the Board, Founder and Chief Executive Office has passed away. We are deeply sorry (news posted on August 26 2019).
James Schoeneck who was Director, becomes Interim Chief Executive Officer (news posted on August 26 2019).
Suzanne Blaug has joined the company as Independent Director (news posted on June 6 2019).
Create an alert
to follow the executive moves at Fibrogen.
WebMD Health has announced the acquisition of Aptus Health (posted on Sep 30, 2019).
Castle Creek Pharmaceuticals has announced the acquisition of Fibrocell Science (posted on Sep 13, 2019).
Medicine Man Technologies has announced the acquisition of MedPharm (posted on Sep 12, 2019).
Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019 | FibroGen, Inc.
FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine | FibroGen, Inc.
FibroGen Receives One of China Pharmaceutical Industry’s Highest Awards for Clinical Innovation for Roxadustat | FibroGen, Inc.
FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis | FibroGen, Inc.
FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy | FibroGen, Inc.
Learn about your clients' org charts. Understand their industries and their competitors.
View the executives' biographies. Contact the executives through our email platform.
Select key words to follow your clients. Receive alerts when executive movements happen.
File your clients in folders. Add private notes. Download our data in Excel on your PC.